In this article we present an update on the pharmacokinetic, pharmacodynamic and clinical studies of the parenteral glycoprotein IIb/IIIa receptor inhibitors available in the Netherlands. These are abciximab (Reopro®), eptifibatide (Integreline®) and tirofiban (Aggrastat®). Glycoprotein IIb/IIIa receptor inhibitors appear to be effective only in combination with percutaneous coronary interventions. The application of glycoprotein IIb/IIIa receptor inhibitors without percutaneous coronary interventions has limited value. Glycoprotein IIb/IIIa receptor inhibitors remain less effective than expected on theoretical grounds. Lots of studies have been performed with inconclusive results. Therefore little answers are available.
|Translated title of the contribution||Many studies, few answers. Glycoprotein IIb/IIIa receptor inhibitors|
|Number of pages||5|
|Publication status||Published - 23 May 2003|